<DOC>
	<DOCNO>NCT01867164</DOCNO>
	<brief_summary>The purpose comparative study evaluate efficacy ovule triple active agent ( terconazole , clindamycin fluocinolone ) versus another ovule triple active agent ( nystatin , metronidazole fluocinolone ) treatment symptom cause presence vaginitis ( inflammation vagina ) bacterial vaginosis ( polymicrobial , nonspecific vaginitis associate positive culture Gardnerella vaginalis anaerobic organisms decrease lactobacillus ) .</brief_summary>
	<brief_title>A Study Compare Efficacy Safety Ovule Containing Terconazole , Clindamycin Fluocinolone Versus Ovule Containing Metronidazole , Nystatin Fluocinolone Treatment Secondary Vulvar/ Vaginal Symptoms Infectious Vaginitis/ Infectious Vaginosis</brief_title>
	<detailed_description>This prospective ( study follow participant forward time ) , open-label ( people know identity intervention ) , randomize ( study drug assign chance ) , comparative , parallel ( clinical trial compare response 2 group participant receive different treatment ) double-arm , multi-center ( 1 hospital medical school team work medical research study ) study . The study consist 3 phase : Screening phase Visit 1 ( Day -3/1 ) ; Inclusion treatment phase Visit 2 ( Day 1 ) ; Treatment monitoring phase ( 3 day treatment ) Visit 3 ( Day 7 Gynoclin V Day 13 Vagitrol V ) Visit 4 ( Day 12 Gynoclin V Day 18 Vagitrol V ) . Participants randomly assign 1 2 treatment group : Gynoclin V Vagitrol V. Participants Gynoclin V group administer 1 ovule ( contain 80 milligram [ mg ] terconazole , 100 mg clindamycin 0.5 mg fluocinolone acetonide ) vaginally every 24 hour night , 3 day . Participants Vagitrol V group administer 1 ovule ( contain 500 mg metronidazole , 0.5 mg fluocinolone acetonide 100,000.00 microgram/milliliter nystatin ) vaginally every 24 hour night , 10 day . Primarily , participant evaluate sign symptom , characteristic vaginal discharge , change vulvar region , change cervix presence bacteria , fungi and/or parasite . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<mesh_term>Terconazole</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Participants present clinical symptom compatible vaginitis/bacterial vaginosis , follow symptom reason consultation : pruritus ( itchiness ) , vulvar burning , well present leukorrhea ( clear white discharge vagina , consist mainly mucus ) accompany symptom Participant agree return 7th 13th day start treatment Participant agree abstain sexual relation 13 day study Participant sign inform consent participate study Participant know allergy vaginal treatment Participants receive treatment current condition 10 day date inclusion , currently receive antibiotic ( drug use stop slow growth germ ) , antifungal , antiparasitics systemic steroid Participant suspect pregnancy currently breastfeed Participant receive unknown drug experimental drug within 3 month inclusion Participant know carrier severe ( serious , life threaten ) disease alters metabolism excretion drug use ( liver kidney disease )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Vaginitis</keyword>
	<keyword>Infectious vaginosis</keyword>
	<keyword>Terconazole</keyword>
	<keyword>Clindamycin</keyword>
	<keyword>Fluocinolone</keyword>
	<keyword>Metronidazole</keyword>
	<keyword>Nystatin</keyword>
</DOC>